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Background:  Clinical  trials  investigated  the  potential  role  of  both  KRAS  and BRAF  mutations,  as  prognostic
biomarkers,  in  colorectal  cancer  (CRC)  patients  who  underwent  surgical  treatment  of CRC-related  liver
metastases  (CLM),  showing  conﬂicting  results.  This  meta-analysis  aims  to  review  all  the studies  reporting
survival outcomes  (recurrence  free  survival  (RFS),  and/or  overall  survival  (OS))  of  patients  undergoing
resection  of  CLM,  stratiﬁed  according  to  KRAS  and/or  BRAF  mutation  status.
Materials  and  methods:  Data  from  all published  studies  reporting  survival  outcomes  (RFS  and/or  OS)  of CRC
patients  who  received  resection  of  CLM,  stratiﬁed  by  KRAS  and/or  BRAF  mutation  status  were  collected,
according  to the  PRISMA  guidelines.  Pooled  HRs  were  calculated  for  both  the OS  and/or  RFS.
Results:  Seven  eligible  trials  (1403  patients)  were  included.  Pooled  analysis  showed  that KRAS  muta-olorectal cancer tions  predicted  a signiﬁcantly  worse  both  RFS  (HR:  1.65;  95%  CI: 1.23–2.21)  and  OS  (HR: 1.86;  95%  CI:
1.51–2.30)  in patients  who  underwent  surgical  resection  of  CLM.  BRAF  mutations  were  also  associated
with  a signiﬁcantly  worse  OS  (HR:  3.90;  95%  CI: 1.96–7.73)  in this  subgroup  of  patients.
Conclusions:  This  meta-analysis  suggests  both  KRAS  and BRAF  mutations  as poor,  prognostic  biomarkers,
associated  with  worse  survival  outcomes,  in patients  undergoing  hepatic  resection  of CLM.
©  2016 Elsevier  Ireland  Ltd.  All  rights  reserved.∗ Corresponding author at: Medical Oncology Director, Section of Medical Oncol-
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1 These authors equally contributed to this work.
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040-8428/© 2016 Elsevier Ireland Ltd. All rights reserved.1. Introduction
The liver is the most common metastatic site (Adam et al., 2009)
in colorectal cancer (CRC) patients. Twenty to twenty-ﬁve percent
(20–25%) of patients have clinically detectable colorectal-related
liver metastases (CLM) at the initial diagnosis and approximately
50% of the patients develop CLM during their disease course
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Garden et al., 2006). Resection of the CLM, sometimes in combina-
ion with other local treatment modalities, such as radiofrequency
blation (RFA), has become the standard of care, and offers the
nly potential for cure (Chiappa et al., 2009; Ksienski et al., 2010).
he development of new surgical approaches, together with an
ncreasing use of the perioperative systemic therapy, have led to
n increase of the percentage of patients potentially eligible for
urative liver resection (Rolfo et al., 2014, 2013; Bronte et al., 2015,
013). In most series, up to 25% of patients presenting with stage IV
RC undergo hepatic resection (Kopetz et al., 2009), with reported
-year survival rates up to 50% (Taylor et al., 2010; Choti et al., 2002;
hua et al., 2011). However over one-half of patients will develop
ecurrence within 2 years (de Jong et al., 2009; Fong et al., 1999;
ordlinger et al., 1996), not getting any long-term survival beneﬁt
rom hepatic resection.
Metastatic colorectal cancer is a very heterogeneous disease,
ith a strong, both clinical and biological variability, among differ-
nt patients (Bronte et al., 2014). Therefore difﬁculties remain in
Fig. 1. Flow-chart of sogy/Hematology 99 (2016) 150–157 151
deciding who  is a good candidate for liver resection. Many studies
have examined several clinical and pathological factors, includ-
ing number and size of CLM, disease-free interval from primary to
CLM, carcinoembryonic antigen (CEA) level, primary tumor stage,
synchronous or metachronous CLM, as potential prognostic deter-
minants of survival after surgical resection of CLM, in order to
establish a preoperative scoring system that is able to predict the
risk of recurrence after resection, and ultimately allows the selec-
tion of those patients who may  beneﬁt more from surgery (Choti
et al., 2002; de Jong et al., 2009; Fong et al., 1999; Nordlinger et al.,
1996; Mann et al., 2004; Nagashima et al., 2006a,b).
To date, there are not molecular biomarkers, approved in the
clinical setting, that are able to predict such biological differences,
favoring the identiﬁcation of patients, at high risk of relapse (Russo
et al., 2009). RAS mutations, including both KRAS and NRAS gene
mutations, have been reported in about 50% of primary CRC, and
have been associated with resistance to the anti-epidermal growth
factor receptor (EGFR) monoclonal antibodies (MoAbs), Cetuximab
tudies selection.
152 F. Passiglia et al. / Critical Reviews in Oncology/Hematology 99 (2016) 150–157
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Fig. 2. Forest plot showing hazard ratio for relapse free survival according to KRAS
nd Panitumumab, in the metastatic disease (Rizzo et al., 2010;
ronte et al., 2011). This has been well exploited by several ran-
omized trials (De Roock et al., 2010; Bokemeyer et al., 2012;
ouillard et al., 2013; Heinemann et al., 2014; Schwartzberg et al.,
014; Van Cutsem et al., 2015; Bokemeyer et al., 2015), that have
verall shown signiﬁcant poorer response rates and inferior sur-
ival outcomes in RAS-mutated patients receiving chemotherapy
lus anti-EGFR MoAbs, compared to RAS-wild type population.
AS mutations represent the only, molecular, predictive biomarker
pproved for clinical use, while their prognostic role is still debated.
everal randomized studies have shown no signiﬁcant survival dif-
erences between KRAS mutated and KRAS wild-type, CRC patients,
ndependently of anti-EGFR therapy (Price et al., 2011; Hecht et al.,
009; Kastrinakis et al., 1995; Russo et al., 1998; Tol et al., 2010),
hile others have demonstrated a prognostic role of KRAS in
dvanced disease (Richman et al., 2009; Maughan et al., 2011;
ejpar et al., 2012). BRAF mutations have been described in about
0% of primary CRC, representing a well-known negative prognos-
ic factor, associated with worse survival outcomes, regardless of
ny treatment received (Ahn et al., 2014).
Several studies have recently investigated the potential role of
RAS and/or BRAF mutations, as prognostic biomarkers, in patients
ho underwent surgical treatment of CLM. The majority of such
tudies have shown that both KRAS and BRAF, respectively detected
n about 30% and 3% of CLM, are associated with worse survival
utcomes of patients undergoing liver resection (Nash et al., 2010;
aragkounis et al., 2013; Vauthey et al., 2013; Stremitzer et al.,
012), while some other studies have not found a signiﬁcant associ-
tion (Kemeny et al., 2014; Teng et al., 2012; Schirripa et al., 2015).
he aim of this meta-analysis is to combine and analyze simulta-
eously all the studies reporting the survival outcomes (recurrence
ree survival (RFS), and/or overall survival (OS)) of patients who
eceived resection of CLM, stratiﬁed by KRAS and/or BRAF muta-
ion status, in order to provide a more precise estimation of the
rognostic value of both KRAS and BRAF, in patients undergoing
urgical therapy for CLM.
ig. 3. Forest plot showing hazard ratio for overall survival according to KRAS mutation stion status in colorectal cancer patients who received resection of liver metastasis.
2. Materials and methods
2.1. Search for clinical trials
We  performed our meta-analysis according to a predeﬁned
written protocol. We  searched for all published studies, that report
the survival outcomes (RFS and/or OS) of patients who received
resection of CLM, stratiﬁed by KRAS and/or BRAF mutation status.
Publications were identiﬁed by an electronic search in Medline,
using PubMed online service, updated in May  2015. The search for
publications was made by other databases including the Cochrane
Library and EMBASE. However the search on PubMed allowed the
widest collection of publications about this topic. The following
search terms were used: “KRAS”, “BRAF”, “colorectal cancer”, “CRC”,
“prognostic”, “liver metastases”, “liver resection” “hepatic surgery”.
The search was limited to human studies in the English language.
The results were supplemented with manual searches of Ameri-
can Society of Clinical Oncology meeting proceedings, references
of selected articles and published reviews. A systematic review on
this topic in the Cochrane database of systematic reviews was  not
found.
2.2. Selection criteria
According to this search clinical trials were taken into account
if they had to fulﬁll all the following inclusion criteria: (1) only
patients with metastatic colorectal cancer were included; (2) only
patients who underwent resection of CLM were included (3) stud-
ies that report the survival outcomes (RFS and/or OS) of patients
who received resection of CLM; (4) studies that report the survival
outcomes (RFS and/or OS), stratiﬁed by KRAS and/or BRAF mutation
status.2.3. Data extraction
Two authors independently selected studies according to the
aforementioned inclusion criteria. If these two authors could not
tatus in colorectal cancer patients who received resection of liver metastasis.
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Table  1
Characteristics of the 7 trials included in the meta-analysis.
Trial (reference) RAS mut  n. (%) BRAF mut  n. (%) KRAS (mut vs wt)
RFS (HR, 95% CI)
KRAS (mut vs
wt)  OS (HR,
95% CI)
BRAF (mut vs wt)
RFS (HR,95% CI)
BRAF (mut vs wt)
OS  (HR, 95% CI)
Schirripa et al.
(2015)
160/309 (52) 12/309 (4) 1.22 (0.94–1.58) 1.08 (0.73–1.59) 2.31 (1.09–4.87) 2.76 (1.12–6.81)
Karagkounis et al.
2013
58/202 (29) 4/202 (2) 1.78 (1.04–2.71) 1.97 (1.20–3.24) N.A 1.90 (0.60–5.99)
Kemeny et al.
(2014)
51/169 (30) 1/162 (0.6) 1.90 (1.12–3.20) 1.99 (0.88–4.51) N.A N.A
Nasch et al. (2010) 51/188 (27) N.A N.A 2.39 (1.41–4.04) N.A N.A
Stremitzer et al.
(2012)
15/60 (25) 0/60 2.48 (1.26–4.89) 3.49 (1.29–9.41) N.A N.A
Teng et al. (2012) 87/231 (37) 5/231 (2) N.A 1.48 (0.86–2.54) N.A 6.23 (1.89–20.61)
Vauthey et al.
(2013)
34/193 (18) N.A 1.92 (1.21–3.03) 2.25 (1.13–4.49) N.A N.A
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FS indicates overall survival; RFS, relapse free survival; mut, mutated; wt, wild typ
R,  hazard ratio; CI, conﬁdence intervals; N.A, not available.
each a consensus, another author was consulted and a ﬁnal deci-
ion was made by consensus. Information was carefully extracted
y overall selected studies. The following data were collected and
rganized from eligible studies: ﬁrst author name, journal and year
f publication, study design, study treatment, baseline characteris-
ics of patients (i.e., age, stage, KRAS status, BRAF status), outcome
easures (i.e., RFS and/or OS), and and hazard ratio (HR) with 95%
onﬁdence intervals (CIs) for RFS and/or OS, stratiﬁed according to
RAS and/or BRAF mutation status. Data extraction was conducted
ccording to the Preferred Reporting Items for Systematic Reviews
nd Meta-Analysis (PRISMA) guidelines (Moher et al., 2010).
.4. Statistical analysis
Patients were stratiﬁed according to KRAS and/or BRAF muta-
ion status into 2 groups: mutant KRAS and/or BRAF and wild-type
RAS and/or BRAF. The outcome measures were OS and RFS, calcu-
ated in KRAS and/or BRAF-mutated patients undergoing resection
f CLM, compared to KRAS and/or BRAF wild-type population. The
orrelation between these endpoints and KRAS/BRAF mutations
as expressed as an HR of KRAS and/or BRAF-mutated patients
ver KRAS/BRAF-wild type patients. Thus, an HR more than 1 indi-
ates that KRAS and/or BRAF-mutations are associated with worse
S and/or RFS after CLM resection. The heterogeneity between
rials was tested using the Cochran Q-test, with a predeﬁned sig-
iﬁcance threshold of 0.1. A meta-analysis of HRs was  performed
o calculate a pooled HR for each outcome using a ﬁxed-effect or
andom-effect, based on statistical signiﬁcance of Q-test, according
o Mantel–Haenszel method. Publication bias for both OS and RFS
nalysis were assessed using Begg’s funnel plots and Egger’s test.
he level of signiﬁcance was set at 5% (P < 0.05 suggested a statisti-
al signiﬁcant publication bias). If publication bias was  found, the
uval and Tweedie nonparametric ‘trim and ﬁll’ method was  used
o adjust it. All statistical analyses were performed with Review
anager 5.3.5 (RevMan; version 5.3.5) and Comprehensive Meta-
nalysis software (CMA; version 3.0).
ig. 4. Forest plot showing hazard ratio for overall survival according to BRAF mutation sumber of patients.
3. Results
Our search, according to the aforementioned criteria, performed
in May  2015, identiﬁed 392 publications. Among these, after a care-
ful selection procedure, only seven studies (1403 patients) met our
inclusion criteria and were included in our meta-analysis (Fig. 1).
Three of these studies were retrospective series (Vauthey et al.,
2013; Kemeny et al., 2014; Francesca Bergamo and Loupakis et al.,
2014), while the others were prospective studies (Nash et al., 2010;
Karagkounis et al., 2013; Stremitzer et al., 2012; Teng et al., 2012).
In these 7 studies, sample sizes of the analyzed population ranged
from 60 (Stremitzer et al., 2012) to 309 (Schirripa et al., 2015),
while the percentage of KRAS mutated patients ranged from 14%
(Stremitzer et al., 2012) to 37% (Teng et al., 2012). BRAF mutations
were analysed in four of the seven included studies (Karagkounis
et al., 2013; Stremitzer et al., 2012; Teng et al., 2012), and it was
found in 2–4% of patients who  underwent surgery for CLM. In nearly
every trial, patients’ characteristics were well balanced between
the two  arms. A detailed list of the seven selected studies, includ-
ing molecular genotyping and patients’ outcomes, are described in
Table 1.
All the included studies analyzed the survival outcomes (OS
and/or RFS) of patients undergoing resection of CLM, stratiﬁed by
KRAS mutation status. Five studies reported HRs with 95% CI data
for both RFS and OS (Karagkounis et al., 2013; Vauthey et al., 2013;
Stremitzer et al., 2012; Kemeny et al., 2014), while two studies
reported only HRs with 95% CI data for OS (Nash et al., 2010; Teng
et al., 2012). Pooled analysis showed that KRAS mutations pre-
dicted a signiﬁcant worse both RFS (HR: 1.53; 95% CI: 1.27–1.83)
and OS (HR: 1.7; 95% CI: 1.38–2.10) in patients who  underwent
surgical resection of CLM (Figs. 2 and 3). The pooled HRs for both
RFS and OS were calculated using ﬁxed-effect model, because of
non-signiﬁcant heterogeneity between treatment effects (Q-test:
P: 0.16; P: 0.11). Only three of the seven included studies analysed
the OS of patients who underwent resection of CLM, according to
BRAF mutation status (Karagkounis et al., 2013; Teng et al., 2012),
tatus in colorectal cancer patients who received resection of liver metastasis.
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hile RFS data have not been reported in any of such studies. Pooled
nalysis showed that BRAF mutations predicted a signiﬁcant worse
S (HR: 3.07; 95% CI: 1.67–5.66) in this subgroup of CRC patients
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ent effects (Q-test: P: 0.35). Publication bias have not been found
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sis, resulted positive for bias (P: 0.0017; P: 0.02). Funnel plots for
Rs of both RFS and OS stratiﬁed by KRAS mutations are reported
n Figs. 5 and 6. However, analysis with the ‘trim and ﬁll’ method
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4. DiscussionThis meta-analysis, including seven studies, which evaluated
the survival outcomes (OS, and/or RFS) of patients undergoing hep-
atic resection of CLM, stratiﬁed by KRAS and/or BRAF mutation
status, has shown that both KRAS and BRAF mutations are asso-
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iated with worse patients’ survival outcomes, compared to KRAS
nd BRAF wild-type population. Indeed both the risk of recurrence
nd death are signiﬁcantly higher in both KRAS and BRAF mutated
ompared to KRAS and BRAF wild-type patients, suggesting a nega-
ive prognostic value of such molecular biomarkers in this subgroup
f patients. Currently, few clinical-pathological factors are con-
idered to predict the recurrence risk and outcomes of patients
ndergoing resection of CLM in clinical practice, but our ability to
dentify patients who may  beneﬁt more from surgical therapies still
ery poor, and very little is known about the biology underlying
he tumor heterogeneity. The role of molecular biomarkers, such
s KRAS and BRAF, is well established in the advanced and unre-
ectable disease, but its potential application in CRC patients with
iver metastases candidate to resection has not been deﬁned yet.
he results of our work suggest both KRAS and BRAF mutations
s negative prognostic biomarkers in patients undergoing surgi-
al therapy for CLM, supporting the evaluation of such molecular
iomarkers together with the other clinical-pathological factors,
n order to more accurately predict, both recurrence risk and sur-
ival of patients undergoing resection of CLM, and ultimately select
nly the best candidates for surgery. Indeed it’s possible that both
RAS and BRAF mutations are associated with a worse biology
nd a more rapid and aggressive metastatic behavior of CLM, dis-
ouraging surgeons to perform surgical resection, independently
f clinical resectability. This interpretation is consistent with the
vidence that the percentage of KRAS mutated patients ranged
rom 14% (Stremitzer et al., 2012) to 37% (Teng et al., 2012) in all
even included studies, compared to 35-45% reported in metastatic
nd unresectable CRC, suggesting a signiﬁcant association between
RAS mutations rates and tumor behavior, as described in pre-
linical studies (Suchy et al., 1992; Tanaka et al., 1994; Varghese
t al., 2002; Webb et al., 1998). Some clinical series have also shown
hat KRAS mutations are associated with an increased risk of devel-
ping lung and liver metastases compared to wild-type population
Vauthey et al., 2013; Kemeny et al., 2014). Others have shown a
igher incidence of lung metastases/recurrence than liver metas-
ases/recurrence in KRAS mutated patients (Vauthey et al., 2013;
ie et al., 2011; Kim et al., 2012). Even if KRAS mutations rate in CLM
sually corresponds with the mutation status of the primary tumor
Tie et al., 2011; Vakiani et al., 2012), it seems to be different among
ifferent metastatic sites, with a higher percentage of mutations
n lung and brain metastases, than in liver metastases (Tie et al.,
011; Kim et al., 2012), suggesting speciﬁc RAS-related patterns of
ecurrence, with potential implication in the clinical management
f CRC patients, but these trends need to be investigated in larger,
rospective studies. As regards BRAF mutations, even if evaluated
n a small subgroup of patients, our ﬁndings are consistent with the
ost part of published studies which have validated BRAF muta-
ions obtained from primary tumour specimens as a strong negative
rognostic biomarker in metastatic CRC (Ahn et al., 2014), show-
ng a more aggressive and chemo-refractory behavior compared
o wild-type tumours (Tran et al., 2011). However it’s interesting
o observe that the percentages of BRAF mutations (2–4%) in all
he included studies is lower than those reported in the literature
5–10%) (Sridhar et al., 2005; Di Nicolantonio et al., 2008), likely
ue to the clinical selection of patients included in such studies.
ndeed, because of their peculiar metastatic spread, BRAF-mutated
umours are usually detected as an advanced disease, rarely can-
idate for liver surgery. The low percentage of BRAF mutations in
uch subgroup of CRC patients, could limit its clinical application as
rognostic biomarker for routinary use, but does not affect neither
ts scientiﬁc relevance, nor its potential implications for individual
atients.
This literature-based meta-analysis conﬁrms the results
chieved in the majority of included studies, suggesting both KRAS
nd BRAF mutations as, negative, prognostic biomarker, in patientsogy/Hematology 99 (2016) 150–157 155
who underwent surgical resection of CLM; however, it has some
limitations. The patients cohorts included in the seven studies of
our meta-analysis are quite heterogeneous, because of different
selection criteria, as well as a variable origin (primary tumor vs
liver metastases) of tissue available for the mutational analysis.
Indeed the mutation status was  determined from liver metastasis
for the majority of patients, while it was  determined from the pri-
mary tumor in about 20% of patients included in both the Kemeny
et al. (2014) and Schirripa et al. (2015) studies. Almost all seven
studies included, performed the evaluation of the most common
KRAS mutations in the extracted DNA (codon12/13); only two  stud-
ies (Vauthey et al., 2013; Schirripa et al., 2015) evaluated both
KRAS and NRAS mutations (codon12/13/61), stratifying patients
according to all RAS mutation status. However, NRAS mutations
account for only 10–20% of all RAS-mutated patients, representing
a very small subgroup of patients included in both studies, likely
not inﬂuencing ﬁnal study results. Almost all the patients included
in our meta-analysis had received peri-operative, 5-FU-based, sys-
temic chemotherapy, with or without bevacizumab. Only a small
percentage of patients had received anti-EGFR MoAbs (11.8% in
the study of Teng et al. (2012), 5% in the study of Schirripa et al.
(2015), and 13 of 28 wild-type KRAS patients who developed recur-
rence, in the study of Stremitzer et al. (2012)). Furthermore two
of the seven studies, included also patients who  received loco-
regional treatments after liver resection, such as adjuvant hepatic
arterial infusion (HAI) (Kemeny et al., 2014), and tumour abla-
tion (Karagkounis et al., 2013). The above described heterogeneity
among the different patients’ cohort, does not reduce the clinical
and statistical signiﬁcance of our results, which reveal both KRAS
and BRAF as poor prognostic biomarker in patients who  underwent
surgical resection of CLM, but limits, of course, any generaliza-
tion to the overall CRC population, as well as its current use as
predominant factor for the upfront patients selection in clinical
practice. Indeed, the lack of a larger individual patient analysis,
including also the other known clinical-pathological prognostic fac-
tors, such as the number and size of CLM, the disease-free interval
from primary to CLM, CEA level, primary tumor stage, etc., does not
allow to consider both KRAS and BRAF mutations as independent
prognostic biomarkers for clinical decision models. Finally, long-
term survival outcomes (10–20 year RFS/OS rate) should be known
before to deﬁnitively exclude CRC patients from surgery, but such
data were not reported in any of included studies. Therefore fur-
ther clinical trials are urgently needed to investigate if KRAS/BRAF
mutated patients undergoing hepatectomy for CLM, have signif-
icantly lower RFS/OS rates compared to the wild type, after a
long-term follow-up, and ultimately recommend, as suggested by
our work, the surgical treatment of CLM only to the wild type pop-
ulation. In conclusion our meta-analysis conﬁrm both KRAS and
BRAF mutations as a strong, prognostic biomarkers, associated with
worse both OS and RFS, in patients undergoing hepatic resection
of CLM. Certainly, these interesting evidences represent the ﬁrst
step towards a deeper understanding of molecular mechanisms
underlying the tumor behavior and patients’ outcomes in a clinical-
selected subgroup of CRC patients, supporting the introduction of
new treatment decision models, taking into account the tumor
molecular proﬁle, together with the other clinical-pathological
factors, in order to predict the outcomes of patients undergoing
resection of CLM, and individualize both systemic and loco-regional
treatment strategies.Conﬂict of interest
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